Alcohol Septal Ablation
Treatment for Hypertrophic Cardiomyopathy
Effectiveness
80%
Safety Score
48%
Clinical Trials
8
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
48
DangerousModerateSafe
Treatment Details
Time to Effect
Immediate obstruction reduction, full symptomatic improvement over weeks to months
Treatment Duration
One-time procedure, lifetime benefit
Evidence Quality
MODERATE-HIGHNumber Needed to Harm (NNH)
7(Treat 7 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100
Monitoring:$500
Side Effect Mgmt:$1,000
Total Annual:$1,600
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$90,000/QALY
QALYs Gained
7
Outcome-Based Costs
Cost per Responder
$2,000
Comparison vs Surgical Septal Myectomy
Cost Difference
$-20,000/year
Less expensive
QALY Difference
-1.00 QALYs
Worse outcomes
Dominance
No dominance
Alcohol Septal Ablation Outcomes
for Hypertrophic Cardiomyopathy
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+80%
Common Side Effects
Complete heart block requiring pacemaker
+15%
Arrhythmias (AFib, VT)
+10%
Pericardial effusion
+5%
Transient chest pain
+30%
Death
+0.8%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
4 completed trials for Alcohol Septal Ablation in Hypertrophic Cardiomyopathy
The Effect of TASH in Patients With HOCM
NCT04066777COMPLETEDNA
24 participants
INTERVENTIONAL
Aarhus N, Denmark
Started: May 29, 2019
Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study
NCT00035386COMPLETEDPHASE2
12 participants
INTERVENTIONAL
Bethesda, United States
Started: Apr 1, 2002
A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy
NCT00001894COMPLETEDPHASE2
70 participants
INTERVENTIONAL
Bethesda, United States
Started: Aug 1, 1999
Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy
NCT04133532COMPLETEDPHASE4
22 participants
INTERVENTIONAL
Prague, Czechia
Started: Mar 5, 2020